DIFFERENTIAL-EFFECTS OF 3 DOPAMINE-RECEPTOR AGONISTS IN MPTP-TREATED MONKEYS

被引:29
作者
ARAI, N
ISAJI, M
MIYATA, H
FUKUYAMA, J
MIZUTA, E
KUNO, S
机构
[1] NATL UTANO HOSP,DEPT NEUROL,KYOTO 616,JAPAN
[2] NATL UTANO HOSP,CLIN RES CTR,KYOTO 616,JAPAN
[3] KISSEI PHARMACEUT CO LTD,PHARMACOL LAB,NAGANO,JAPAN
关键词
DOPAMINE RECEPTOR AGONISTS; PARKINSONS DISEASE; PARKINSONISM; HYPERACTIVITY;
D O I
10.1007/BF02256629
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The behavioral effects of cabergoline, pergolide and bromocriptine were investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys with attention to the induction of hyperactivity, as evidenced by irritability, excitability and aggressiveness. All three drugs improved the parkinsonism in a dose-dependent fashion following a single injection. Among the three dopamine (DA) receptor agonists used, the antiparkinsonian effect of pergolide was the strongest and had an immediate effect, while cabergoline showed the longest duration of the antiparkinsonian effect and was least potent in inducing hyperactivity.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 10 条
  • [1] BEHAVIORAL INVOLVEMENT OF CENTRAL DOPAMINE D-1 AND D-2 RECEPTORS IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE(MPTP)-LESIONED PARKINSONIAN CYNOMOLGUS MONKEYS
    AKAI, T
    OZAWA, M
    YAMAGUCHI, M
    MIZUTA, E
    KUNO, S
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1995, 67 (02) : 117 - 124
  • [2] A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE
    BURNS, RS
    CHIUEH, CC
    MARKEY, SP
    EBERT, MH
    JACOBOWITZ, DM
    KOPIN, IJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14): : 4546 - 4550
  • [3] CALNE DB, 1993, NEW ENGL J MED, V329, P1021
  • [4] LEVODOPA-INDUCED DYSKINESIA AND RESPONSE FLUCTUATIONS IN PRIMATES RENDERED PARKINSONIAN WITH 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP)
    CLARKE, CE
    SAMBROOK, MA
    MITCHELL, IJ
    CROSSMAN, AR
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1987, 78 (03) : 273 - 280
  • [5] CLEMENS JA, 1993, ARZNEIMITTEL-FORSCH, V43-1, P281
  • [6] LONG-LASTING PROLACTIN-LOWERING EFFECT OF CABERGOLINE, A NEW DOPAMINE AGONIST, IN HYPERPROLACTINEMIC PATIENTS
    FERRARI, C
    BARBIERI, C
    CALDARA, R
    MUCCI, M
    CODECASA, F
    PARACCHI, A
    ROMANO, C
    BOGHEN, M
    DUBINI, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) : 941 - 945
  • [7] PSYCHIATRIC SIDE EFFECTS OF LEVODOPA IN MAN
    GOODWIN, FK
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1971, 218 (13) : 1915 - +
  • [8] CABERGOLINE IN PARKINSONS-DISEASE - LONG-TERM FOLLOW-UP
    LERA, G
    VAAMONDE, J
    RODRIGUEZ, M
    OBESO, JA
    [J]. NEUROLOGY, 1993, 43 (12) : 2587 - 2590
  • [9] ON-OFF EFFECTS IN PATIENTS WITH PARKINSONS-DISEASE ON CHRONIC LEVODOPA THERAPY
    MARSDEN, CD
    PARKES, JD
    [J]. LANCET, 1976, 1 (7954) : 292 - 296
  • [10] STEIGER MJ, 1992, HDB PARKINSONS DIS, P391